Tofersen, an antisense oligonucleotide targeting superoxide dismutase 1 (SOD1), was granted accelerated approval by the FDA in 2023 for the 2–3% of familial ALS patients carrying this genetic mutation. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.